Product

FLU-IGIV

Aliases

Anti-influenza immunoglobulin intravenous (Human), NP-025

1 clinical trial

2 indications

Indication

Influenza A/H3N2

Indication

Influenza A H1N1

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients With Serious Influenza A Infection

Status: Completed, Estimated PCD: 2019-06-17